{"url_path":"/sec/apm/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","accession_number":"0001213900-26-079416","cik":"0001734005","ticker":"APM","issuer_name":"Niki BioSolutions, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1734005/0001213900-26-079416-index.html","primary_entity_key":"0001734005","primary_entity_name":"Niki BioSolutions, Inc."},"word_count":403,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n*(a) Financial\nStatements of Businesses or Funds Acquired.*\n\n \n\nThe financial statements required\nby Item 9.01(a) of Form 8-K will be filed by amendment to this Current Report on Form 8-K no later than 71 days after the date this report\non Form 8-K must be filed.\n\n \n\n*(b)* *Pro\nForma Financial Information.*\n\n \n\nThe\npro forma financial statements required by Item 9.01(b) of Form 8-K will be filed by amendment to this Current Report on Form 8-K no later\nthan 71 days after the date this report on Form 8-K must be filed.\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit**\n \n**Description**\n\n2.1\n \n[Merger Agreement by and between Aptorum and DiamiR, dated July 14, 2025 (1)](https://www.sec.gov/Archives/edgar/data/1734005/000121390025066642/ea024961501ex2-1_aptorum.htm)\n\n3.1\n \n[Articles of Incorporation for Niki BioSolutions, Inc. (Filed herewith)](ea029826201ex3-1.htm)\n\n3.2\n \n[Form of Bylaws for Niki BioSolutions, Inc.\n(Filed herewith)](ea029826201ex3-2.htm)\n\n3.3\n \n[Certificate of designation of the preferences, rights and limitations creating the Series A Preferred Stock (Filed herewith)](ea029826201ex3-3.htm)\n\n10.1\n \n[Management Services Agreement by and between Aptorum Therapeutics and DiamiR, dated July 14, 2025 (1)](https://www.sec.gov/Archives/edgar/data/1734005/000121390025066642/ea024961501ex10-1_aptorum.htm)\n\n10.2\n \n[Intellectual Property License Agreement by and between Aptorum Therapeutics, DiamiR LLC, and DiamiR, dated July 14, 2025 (1)](https://www.sec.gov/Archives/edgar/data/1734005/000121390025066642/ea024961501ex10-2_aptorum.htm)\n\n10.3\n \n[Voting and Support Agreement by and between Aptorum and its major shareholder, dated July 14, 2025 (1)](https://www.sec.gov/Archives/edgar/data/1734005/000121390025066642/ea024961501ex10-3_aptorum.htm)\n\n10.4\n \n[Form of Stockholders Agreement (Filed herewith)](ea029826201ex10-4.htm)\n\n10.3\n \n[Amendment to the Management Services Agreement dated as of December 2, 2025 (2)](https://www.sec.gov/Archives/edgar/data/1734005/000121390025118748/ea026868301ex10-3_aptorum.htm)\n\n10.4\n \n[Second Amendment to the Management Services Agreement dated as of March 10, 2026 (3)](https://www.sec.gov/Archives/edgar/data/1734005/000121390026034753/ea028217201ex10-3_aptorum.htm)\n\n10.5\n \n[Third Amendment to the Management Services Agreement dated as of June 22, 2026 (4)](https://www.sec.gov/Archives/edgar/data/1734005/000121390026070672/ea029496701ex10-5.htm)\n\n99.1\n \n[Press Release (Filed herewith)](ea029826201ex99-1.htm)\n\n99.2\n \n[2026 Incentive Plan (Filed herewith)](ea029826201ex99-2.htm)\n\n \n\n*Certain schedules have been omitted pursuant to Item 601(a)(5) of\nRegulation S-K. A copy of any omitted schedule will be furnished to the SEC upon request.\n\n** **\n\n(1)Incorporated by reference to the Current Report on Form 6-K\nfiled on July 22, 2025\n\n(2)Incorporated by reference to the Current Report on Form 6-K/A\nfiled on December 5, 2025\n\n(3)Incorporated by reference to the Current Report on Form 6-K/A\nfiled on March 26, 2026\n\n(4)Incorporated by reference to the Current Report on Form 6-K/A\nfiled on June 22, 2026\n\n \n\n3\n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: July 20, 2026\n\n \n\n \n**NIKI BIOSOLUTIONS, INC.**\n\n \n \n \n\n \nBy:\n*/s/ Ian Huen*\n\n \n \nIan Huen\n\n \n \nChief Executive Officer\n\n \n\n4"}